Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Complement pathways

M Kathryn Liszewski, PhD
John P Atkinson, MD
Section Editors
E Richard Stiehm, MD
Peter H Schur, MD
Deputy Editor
Anna M Feldweg, MD


The complement system is an ancient host defense system that is part of innate and adaptive immunity. It guards the host's intravascular space by opsonizing and lysing bacteria. In addition, it promotes the local acute inflammatory response, which in turn instructs and influences the adaptive immune response. The complement system consists of plasma proteins of the activating cascades and membrane regulators and receptors. The plasma proteins interact via three major cascades: the classical, alternative, and lectin pathways [1-5].

A review of the complement pathways is presented here. Other discussions of the complement system and associated diseases, as well as an overview of the innate immune system, are presented separately. (See "Overview and clinical assessment of the complement system" and "Inherited disorders of the complement system" and "Acquired deficiencies of the complement system" and "An overview of the innate immune system".)


Proteins of the complement activation pathways circulate in the plasma and are present at a lower concentration in other body fluids as well as in the intracellular space. The components in plasma are predominantly synthesized in the liver while the components at other sites represent a combination of local synthesis (many cell types) and filtration from plasma (table 1). (See "Regulators and receptors of the complement system".)


The primary goal of the complement system is the destruction of microbes. This is accomplished through the deposition of large quantities of C3b on a target. This process, known as opsonization, refers to the coating of targets with complement ligands to promote their elimination through immune adherence and phagocytosis by cells bearing complement receptors. Opsonization also facilitates the adaptive immune response including antigen presentation and retention as well as immunologic memory and costimulation of B lymphocytes through the antigen receptor. C3b is partially degraded to iC3b and C3d fragments that also interact with their receptors on phagocytes and immune cells.

A second goal of the complement system is promotion of the inflammatory response, primarily through the liberation of peptides C3a and C5a, known as anaphylatoxins. These approximately 10 kDa peptides bind to their receptors to promote vasodilation, chemotaxis, and other cell activation phenomena.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: May 7, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058.
  2. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140.
  3. Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol 2004; 113:585.
  4. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25:1265.
  5. Wallis R, Mitchell DA, Schmid R, et al. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology 2010; 215:1.
  6. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785.
  7. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34.
  8. Gaboriaud C, Ling WL, Thielens NM, et al. Deciphering the fine details of c1 assembly and activation mechanisms: "mission impossible"? Front Immunol 2014; 5:565.
  9. Ollert MW, Kadlec JV, David K, et al. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 1994; 153:2213.
  10. Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 2007; 19:301.
  11. Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol 1996; 61:201.
  12. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729.
  13. Degn SE, Thiel S, Jensenius JC. New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology 2007; 212:301.
  14. Runza VL, Schwaeble W, Männel DN. Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 2008; 213:297.
  15. Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003; 21:547.
  16. Degn SE, Jensen L, Hansen AG, et al. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol 2012; 189:3957.
  17. Stengaard-Pedersen K, Thiel S, Gadjeva M, et al. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med 2003; 349:554.
  18. Gros P, Milder FJ, Janssen BJ. Complement driven by conformational changes. Nat Rev Immunol 2008; 8:48.
  19. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176:1305.
  20. Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol 2009; 104:115.
  21. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010; 9:43.
  22. Seitz M. Toll-like receptors: sensors of the innate immune system. Allergy 2003; 58:1247.
  23. Hajishengallis G, Lambris JD. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 2010; 31:154.
  24. Forneris F, Ricklin D, Wu J, et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010; 330:1816.
  25. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682.
  26. Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 2004; 24:6457.
  27. Thielens NM, Tacnet-Delorme P, Arlaud GJ. Interaction of C1q and mannan-binding lectin with viruses. Immunobiology 2002; 205:563.
  28. Alexander JJ, Anderson AJ, Barnum SR, et al. The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration. J Neurochem 2008; 107:1169.
  29. McGrath FD, Brouwer MC, Arlaud GJ, et al. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol 2006; 176:2950.
  30. Liszewski MK, Kolev M, Le Friec G, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 2013; 39:1143.
  31. Kolev M, Le Friec G, Kemper C. Complement--tapping into new sites and effector systems. Nat Rev Immunol 2014; 14:811.
  32. Farries TC, Steuer KL, Atkinson JP. Evolutionary implications of a new bypass activation pathway of the complement system. Immunol Today 1990; 11:78.
  33. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 2010; 28:131.